Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
- 29 July 2021
- journal article
- letter
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 21 (9), 1212-1213
- https://doi.org/10.1016/s1473-3099(21)00420-5
Abstract
No abstract availableFunding Information
- German Centre for Infection Research
- European Commission
- BMBF Berlin
This publication has 6 references indexed in Scilit:
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trialThe Lancet, 2021
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationThe New England Journal of Medicine, 2021
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 VaccinationThe New England Journal of Medicine, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021Morbidity and Mortality Weekly Report (MMWR), 2021